ERBB2 and cancer: It boosts natural killer (NK) cell cytotoxicity by upregulating CD107a expression and enhances the efficacy of anti-HER2 therapies (e.g., trastuzumab and T-DM1) by promoting antibody endocytosis and suppressing cancer stem cell renewal.